Breaking News

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

By Zacks Investment ResearchOct 06, 2019 10:17PM ET
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
By Zacks Investment Research   |  Oct 06, 2019 10:17PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Thermo Fisher Scientific Inc. (NYSE:TMO) recently closed the acquisition of a drug substance manufacturing site of GlaxoSmithKline plc (NYSE:GSK) in Cork, Ireland much ahead of schedule.

Valued at 90 million euros, the deal was completed following the fulfillment of all required regulatory approvals. The site will enable Thermo Fisher to meet customer demand for the commercial production of complex active pharmaceutical ingredients (APIs). This remains integral to the company’s efforts to expand its pharmaceutical services footprint internationally.

Acquisition in Detail

The Cork plant is known for producing highly specialized APIs, used for treating diseases like pediatric cancer, depression and Parkinson’s. Thermo Fisher informed that the site is equipped with several facilities, which will enable process development, scale-up and physical characterization of APIs.

As stated earlier, following the conclusion of the acquisition, Thermo Fisher will continue to manufacture APIs for GlaxoSmithKline under a multi-year supply agreement and intends to use the manufacturing hub for developing and producing complex APIs for other customers as well.

Undoubtedly, this transaction aligns with Thermo Fisher’s strategy of enhancing the capabilities of its Pharma Services through the right balance of capital investments as well as mergers and acquisitions.

On the deal’s culmination, the site has now been incorporated with the Laboratory Products and Services segment of Thermo Fisher’s Pharma Services business.

In a separate press release, Thermo Fisher noted that the Cork site will join 1300 colleagues across the company’s expanded API network of manufacturing facilities in Florence and Greenville SC; Linz, Austria and Regensburg, Germany. Apart from adding API development and commercial capabilities, this is going to improve Thermo Fisher’s pharma services offering.

Market Prospects

Per Mordor Intelligence, the global API market was valued at $165.74 billion in 2018. This is projected to reach $236.7 billion by 2024, witnessing a CAGR of 6.1%. Therefore this acquisition is well-timed for Thermo Fisher.

The API Expansion Plan at a Glance

In 2019, Thermo Fisher plans to invest more than $270 million in expanding its capabilities, capacity and talent globally. In this regard, the company opened a virtual reality training center in North Carolina. It has also announced extension of sterile fill finish sites in Greenville, NC and Monza, Italy; expansion of its clinical trials supply and distribution capabilities in India, Argentina and China; and growth of its new viral vector manufacturing sites in Alachua, FL and Cambridge, MA. The business also plans to launch a viral vector manufacturing facility in Lexington, MA, later this year.

Other Growth Efforts

Among other strategic developments, we make a note of Thermo Fisher acquiring the Advanced Bioprocessing business from Becton, Dickinson and Company (NYSE:BDX) , which is expected to significantly widen the company’s Life Sciences Solutions line of offerings.

This apart, the company has entered into an agreement with Eli Lilly and Company (NYSE:LLY) for developing a companion diagnostic that will use the FDA-approved, next-generation sequencing-based Oncomine Dx Target (NYSE:TGT) Test to identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Eli Lilly and Company (LLY): Free Stock Analysis Report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Original post

Zacks Investment Research
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email